MUC1-specific targeting immunotherapy with bispecific antibodies: Inhibition of xenografted human bile duct carcinoma growth

Cancer Research

Volumn 56, Issue 18, 1996, Pages 4205-4212

  Katayose, Yu ^a   Kudo, Toshio ^b   Suzuki, Masanori ^a   Shinoda, Masao ^a   Saijyo, Susumu ^a   Sakurai, Naoki ^a   Saeki, Hisaaki ^b   Fukuhara, Kenji ^a   Imai, Kohzo ^c   Matsuno, Seiki ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; CA-15-3 ANTIGEN; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, SCID; MUROMONAB-CD3; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 9544225180     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Suzuki, M , Takahashi, T., Ouchi, K., and Matsuno, S The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system. Cancer (Phila.), 64: 658-666, 1989
2. Titus, J A., Garrido, M. A , Hecht, T. T , Winkler, D. F., Wunderlich, J. R., and Segal, D M. Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J. Immunol., 138: 4018-4022, 1987.
3. Nitta, T., Sato, K., Yagita, H., Okumura, K , and Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335: 368-371, 1990.
4. 51Cr release assays. J. Immunol. 150: 2305-2315, 1993.
5. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C., Trumper, L., Hartmann, F., Diehl, V., van Lier, R., and Pfreundschuh, M Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells Science (Washington DC), 264: 833-835, 1994
6. Hinoda, Y., Arimura, Y., Itoh, F., Adachi, M., Tsujisaki, M., Imai, K , and Yachi, A. Primary structure of the variable regions of a monoclonal antibody MUSE11 recognizing the tandem repeat domain of a mucin core protein, MUC1 J Clin Lab. Anal., 7: 100-104, 1993.
7. McKinney, M. M., and Parkinson, A. A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J. Immunol. Methods, 96: 271-278, 1987
8. Van Lier, R. A., Brouwer, M , and Aarden, L. A. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur. J Immunol., 18 167-172, 1988.
9. Saijyo, S., Kudo, T., Suzuki, M , Katayose, Y., Shinoda, M., Muto, T., Fukuhara, K., Suzuki, T , and Matsuno, S. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1 Tohoku J. Exp. Med., 177: 61-71, 1995
10. Miyagiwa, M., Ichida, T., Tokiwa, T., Sato, J., and Sasaki, H A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell & Dev. Biol., 25: 503-510, 1989.
11. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65: 55-63, 1983.
12. Saijyo, S., Kudo, T , Katayose, Y., Saeki, H , Chiba, N , Suzuki, M , Tominaga, T., and Matsuno, S A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma. Tohoku J. Exp. Med., 178, 113-127, 1996.
13. Schmidt-Wolf, I G., Negrin, R. S., Kiem, H. P , Blume, K G., and Weissman, I L Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity J Exp. Med., 174: 139-149, 1991
14. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol., 153: 1687-1696, 1994
15. van der Bruggen, P , Traversan, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B , Knuth, A., and Boon, T A gene encoding an antigen recognized by cyiolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
16. Kawakami, Y., Eliyahu, S., Delgado, C. H , Robbins, P. F, Rivoltini, L., Topalian, S L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor Proc. Natl Acad. Sci. USA, 91: 3515-3519, 1994.
17. Kawakami, Y., Eliyahu, S , Delgado, C. H., Robbins, P. F., Sakaguchi, K , Appella, E., Yannelli, J. R., Adema, G J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA, 91: 6458-6462, 1994.
18. Rosenberg, S. A , Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S E., Matory, Y. L , Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C A., Simpson, C , and Reichert, C M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313: 1485-1492, 1985.
19. Rosenberg, S. A., Lotze, M T., Muul, L. M., Chang, A. E , Avis, F P., Leitman, S , Linehan, W. M., Robertson, C. N., Lee, R E., Rubin, J. T., Seipp, C. A. Simpson, C. G., and White, D. E A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med , 316: 889-897, 1987.
20. Perez, P., Hoffman, R. W., Shaw, S, Bluestone, J A., and Segal, D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature (Lond.), 316: 354-356, 1985.
21. Moretta, A., Ciccone, E , Pantaleo, G., Tambussi, G., Bottino, C., Melioli, G., Mingari, M. C., and Moreita, L Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans. Immunol. Rev., 111: 145-175, 1989.
22. Hilkens, J , Buijs, F , Hilgers, J , Hageman, P., Calafat, J., Sonnenberg, A., and van der Valk, M Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer, 34: 197-206, 1984
23. Kotera, Y., Fontenot, J. D , Pecher, G., Metzgar, R S., and Finn, O. J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res , 54: 2856-2860, 1994.
24. Nakamon, S., Ota, D, M., Cleary, K. R., Shirotani, K., and Irimura, T. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma Gastroenterology. 106: 353-361, 1994.
25. Burchell, J , Taylor-Papadimitriou, J., Boshell, M , Gendler, S , and Duhig, T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer, 44: 691-696, 1989.
26. Ioannides, C G , Fisk, B., Jerome, K. R., Irimura, T , Wharton, J. T , and Finn, O J T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol , 151: 3693-3703, 1993.
27. Ban, T , Imai, K , and Yachi, A Immunohistological and immunochemical characterization of a novel pancreatic cancer-associated antigen MUSE11. Cancer Res , 49: 7141-7146, 1989.
28. Hinoda, Y., Kakiuchi, H., Nakagawa, N , Ohe, Y., Sugiyama, T., Tsujisaki, M., Imai, K., and Yachi, A. Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin-comparison of antigen MUSElI with CA15-3 Gastroenterol. Jpn., 27, 390-395, 1992.
29. Yamashita, K., Yonezawa, S , Tanaka, S., Shirahama, H , Sakoda, K , Imai, K., Xing, P. X., McKenzie, I F., Hilkens, J., Kim, Y. S., and Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma Int. J. Cancer, 55: 82-91, 1993.
30. Aruffo, A., and Seed, B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl. Acad. Sci. USA, 84: 8573-8577, 1987.
31. Urdahl, K. B., Jenkins, M. K , and Norton, S D. Accessory cell-derived costimulatory signals regulate T cell proliferation. Ann. NY Acad. Sci., 636, 33-42, 1991.
32. Pohl, C., Denfeld, R., Renner, C., Jung, W., Bohlen, H., Sahin, U., Hombach, A , van Lier, R , Schwonzen, M., Diehl, V., and Pfreundschuh, M. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma [Published erratum, Int. J. Cancer, 57: 294, 1994], Int. J. Cancer, 54: 820-827, 1993
33. Kroesen, B. J , Bakker, A., van Lier, R. A., The, H. T., and de Leij, L. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res., 55: 4409-4415, 1995.
34. 2 bispecific monoclonal antibody. Br. J. Cancer, 72 928-933, 1995.
35. Brunda, M. J. Interleukin-12. J. Leukocyte Biol., 55: 280-288, 1994
36. Gately, M. K., Wolitzky, A. G., Quinn, P. M , and Chizzonite, R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol., 143: 127-142, 1992.
37. Mosmann, T R., and Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 7: 145-173, 1989
38. Trinchieri, G. Interleukin-12 and its role m the generation of TH1 cells. Immunol. Today, 14: 335-338, 1993
39. Manetti, R., Parronchi, P., Giudizi, M G , Piccinni, M. P., Maggi, E., Trinchieri, G., and Romagnani, S. Natural killer cell stimulatory factor interleukin 12 (IL-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med., 177: 1199-1204, 1993.
40. Kuge, S , Miura, Y., Nakamura, Y , Mitomi, T., Habu, S , and Nishimura, T Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy. J. Immunol , 154: 1777-1785, 1995.